Lebrikizumab is a monoclonal antibody that binds to the interleukin-13 , a signaling molecule involved in the inflammatory response associated with asthma.First, it is unclear whether the clinics can easily measure the levels of periostin, said Georis. It would be crucial in determining who would and who wouldn t benefit from the drug.
IU Bloomington geologists Claudia Johnson and Erika Elswick, both participants in the Environmental Geochemistry and Health Study, also collected samples of water of the Caribbean Sea. Liu has studied the antimony content of the samples.
SOURCES: Steve Georis, MD, Professor of Medicine, Division of Pulmonary and Critical Care, University of Rochester Medical Center, Rochester, NY, Susanna Von Essen, MD, professor of pulmonary and critical care medicine, University of Nebraska Medical Center in Omaha, in August. 3, 2011, New England Journal of Medicine
In addition, this innovation in blocking IL-13, so maybe this is the beginning of a series of drugs that attack the molecule of IL-13 and maybe they’ll find something inhaled or something that can swallow, he said.
Although glucocorticoids also inhibit IL-13, the molecule is able to exert its influence through other means that have so far escaped the drugs currently used. But the work differently than steroids lebrikizumab traditional.
The drug, lebrikizumab, target a specific receptor involved in asthma, and appears to be the first drug to be successful in this particular approach, said Dr. Steve Georis, a professor of medicine at the Division of Pulmonary and Critical Care at University of Rochester Medical Center.
However, in the group with low periostin, the improvement was only 1.6 % more.
After three months, the group of patients taking lebrikizumab saw a 5.5 % improvement in FEV1 , which measures how much a person excretes in the end, compared to placebo.
While all the side effects were about the same in both groups, there were more effects in the group lebrikizumab musculoskeletal .
The authors randomized 219 adults who had not responded to standard therapy to receive placebo or lebrikizumab.
And ‘perhaps the first drug to have this specific effect in asthmatics, and can lead to gains of more individualized treatment for patients.
Patients who had levels of IL-13 high saw an improvement of 8.2 % with lebrikizumab FEV1 compared to placebo.
Besides the fact that the drug has not yet been approved, lebrikizumab may have other questions.